Search research articles
Contact Us
Filters
Showing results (1041-1050 of 1,298) with videos related to
Page
of 130
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)
|
October 7, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
Carol J Fabian, Bruce F Kimler, Teresa A Phillips, et al.
Cancer Treatment and Research
|
January 5, 2002
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer
Gordon B Mills, Astrid Eder, Xianjun Fang, et al.
American Journal of Human Genetics
|
February 21, 2012
Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man
Karin Tuschl, Peter T Clayton, Sidney M Gospe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Katherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell
|
March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun, Jun Yin, Yong Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer
Yinghui Guan, Wen-Lin Kuo, Jackie L Stilwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2018
<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma
Frederik Holst, Henrica M J Werner, Siv Mjøs, et al.
Cancer Cell
|
March 16, 2017
Integrated Molecular Characterization of Uterine Carcinosarcoma
Andrew D Cherniack, Hui Shen, Vonn Walter, et al.
Journal of the National Cancer Institute
|
June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO
David M Euhus, Kristin C Smith, Linda Robinson, et al.
Page
of 130
Search research articles
Search
Showing results (1041-1050 of 1,298) with videos related to
Sort By:
Page
of 130
Cancer Prevention Research (Philadelphia, Pa.)
|
October 7, 2015
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women
Carol J Fabian, Bruce F Kimler, Teresa A Phillips, et al.
Cancer Treatment and Research
|
January 5, 2002
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer
Gordon B Mills, Astrid Eder, Xianjun Fang, et al.
American Journal of Human Genetics
|
February 21, 2012
Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man
Karin Tuschl, Peter T Clayton, Sidney M Gospe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Katherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell
|
March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun, Jun Yin, Yong Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer
Yinghui Guan, Wen-Lin Kuo, Jackie L Stilwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Muling Mao, Feng Tian, John M Mariadason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2018
<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma
Frederik Holst, Henrica M J Werner, Siv Mjøs, et al.
Cancer Cell
|
March 16, 2017
Integrated Molecular Characterization of Uterine Carcinosarcoma
Andrew D Cherniack, Hui Shen, Vonn Walter, et al.
Journal of the National Cancer Institute
|
June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO
David M Euhus, Kristin C Smith, Linda Robinson, et al.
Page
of 130